Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Healios K K has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 3 distinct examiners and 3 distinct art units, indicating separate examination paths for each action.
BERKE-SCHLESSEL, DAVID W is the busiest examiner with 1 pending matter. Counsel should coordinate the portfolio’s technical positions while adapting arguments to each independent examiner and art-unit setting.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BERKE-SCHLESSEL, DAVID W | 1 | 66.8% | +31.5% |
| LEVIN, JOEL D | 1 | 58.1% | +35.2% |
| TAKENAKA, RISA | 1 | 26.1% | +100.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18834874 | PRODUCTION METHOD FOR NATURAL KILLER CELLS | LEVIN, JOEL D | — |
| 18000030 | HYPOIMMUNOGENIC CELLS | TAKENAKA, RISA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18897981 | EXPANSION OF STEM CELLS IN HOLLOW FIBER BIOREACTORS | BERKE-SCHLESSEL, DAVID W | — |
| 18834874 | PRODUCTION METHOD FOR NATURAL KILLER CELLS | LEVIN, JOEL D | — |
| 18000030 | HYPOIMMUNOGENIC CELLS | TAKENAKA, RISA | — |
| Art Unit | Apps |
|---|---|
| 1651 | 1 |
| 1633 | 1 |
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18897981 | EXPANSION OF STEM CELLS IN HOLLOW FIBER BIOREACTORS | BERKE-SCHLESSEL, DAVID W | 1651 | §103 | Non-Final OA | — | Pending | Sep 26, 2024 |
| 18834874 | PRODUCTION METHOD FOR NATURAL KILLER CELLS | LEVIN, JOEL D | 1633 | §103§112 | Non-Final OA | — | Pending | Jul 31, 2024 |
| 18000030 | HYPOIMMUNOGENIC CELLS | TAKENAKA, RISA | 1632 | §102§112 | Non-Final OA | — | Pending | Nov 28, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHealios K K has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
David W Berke-Schlessel has the most, with 1 of Healios K K's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
